BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1155 related articles for article (PubMed ID: 31711924)

  • 1. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer.
    Liu M; Zhang Y; Yang J; Zhan H; Zhou Z; Jiang Y; Shi X; Fan X; Zhang J; Luo W; Fung KA; Xu C; Bronze MS; Houchen CW; Li M
    Gastroenterology; 2021 Apr; 160(5):1771-1783.e1. PubMed ID: 33421513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB.
    Zhang Y; Bharadwaj U; Logsdon CD; Chen C; Yao Q; Li M
    Clin Cancer Res; 2010 Mar; 16(5):1423-30. PubMed ID: 20160059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism.
    Liu M; Yang J; Zhang Y; Zhou Z; Cui X; Zhang L; Fung KM; Zheng W; Allard FD; Yee EU; Ding K; Wu H; Liang Z; Zheng L; Fernandez-Zapico ME; Li YP; Bronze MS; Morris KT; Postier RG; Houchen CW; Yang J; Li M
    Clin Cancer Res; 2018 Jul; 24(13):3186-3196. PubMed ID: 29615456
    [No Abstract]   [Full Text] [Related]  

  • 5. ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.
    Yang J; Zhang Z; Zhang Y; Ni X; Zhang G; Cui X; Liu M; Xu C; Zhang Q; Zhu H; Yan J; Zhu VF; Luo Y; Hagan JP; Li Z; Fang J; Jatoi A; Fernandez-Zapico ME; Zheng L; Edil BH; Bronze MS; Houchen CW; Li YP; Li M
    Gastroenterology; 2019 Feb; 156(3):722-734.e6. PubMed ID: 30342032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
    Liu F; Gore AJ; Wilson JL; Korc M
    PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
    Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
    Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
    Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
    Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
    Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
    Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts.
    Li M; Zhang Y; Bharadwaj U; Zhai QJ; Ahern CH; Fisher WE; Brunicardi FC; Logsdon CD; Chen C; Yao Q
    Clin Cancer Res; 2009 Oct; 15(19):5993-6001. PubMed ID: 19755388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W; Jesnowski R; Löhr JM
    Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.
    Li M; Zhang Y; Liu Z; Bharadwaj U; Wang H; Wang X; Zhang S; Liuzzi JP; Chang SM; Cousins RJ; Fisher WE; Brunicardi FC; Logsdon CD; Chen C; Yao Q
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18636-41. PubMed ID: 18003899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
    Revalde JL; Li Y; Wijeratne TS; Bugde P; Hawkins BC; Rosengren RJ; Paxton JW
    Eur J Pharmacol; 2017 May; 803():167-173. PubMed ID: 28365185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.